A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML (Q65394653)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML |
clinical trial |
Statements
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates (English)
0 references
4 October 2016
0 references
October 2020
0 references
40
0 references
60 year
0 references